SUBSCRIBE
SUBSCRIBE
News   Drug Development

Neuren Pharmaceuticals Limited to Move to Phase 2 Trial of NNZ-2566 on TBI

September 20, 2007 | 
1 min read

Sydney, Sep 20, 2007 -- Neuren Pharmaceuticals has completed cohorts 1 and 2 of its Phase 1b trial to test the safety, tolerability and pharmacokinetic action of NNZ-2566 as a compound to treat traumatic brain injury (TBI).

Clinical research Phase I Australia
MORE ON THIS TOPIC
Contemporary art collage of a hand holding scissors. Copy space for ad. Modern design.
Immunology and inflammation
Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Medical technology. Doctor holding health icon with dna, electronic medical record. Digital healthcare and research with global network connection on hologram virtual screen, insurance, digital health technology
Partnered
Ending the Diagnostic Odyssey for Patients
December 11, 2024
 · 
4 min read
 · 
BioSpace Insights
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac